Incyte (INCY) Intangibles (2010 - 2026)
Incyte's (INCY) quarterly Intangibles came in at $103.2 million in Q2 2026, down 18.37% YoY from $126.4 million in Q2 2025, and down 6.33% on a QoQ basis from $110.2 million in Q1 2026.
Incyte (INCY) Intangibles (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Intangibles data on file, last reported at $103.2 million in Q2 2026.
- Quarterly Intangibles fell 18.37% year-over-year to $103.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $103.2 million (down 18.37% YoY) and the FY2025 annual result came in at $117.1 million, up 2.92% from the prior year.
- Intangibles eased to $103.2 million in Q2 2026, from $110.2 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $145.4 million in Q1 2022 to a low of $103.2 million in Q2 2026.
- A 5-year average of $123.7 million and a median of $121.8 million in 2023 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2025 — Intangibles gained 11.35% — and 2026, when it decreased 18.37%.
- Tracing INCY's Intangibles over 5 years: stood at $129.2 million in 2022, then declined by 4.39% to $123.5 million in 2023, then slipped by 7.89% to $113.8 million in 2024, then climbed by 2.92% to $117.1 million in 2025, then retreated by 11.9% to $103.2 million in 2026.
- The last three Intangibles figures came in at $103.2 million (Q2 2026), $110.2 million (Q1 2026), and $117.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 103.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.20 Mn |
| Mar 31, 2026 | 110.16 Mn |
| Dec 31, 2025 | 117.13 Mn |
| Sep 30, 2025 | 119.42 Mn |
| Jun 30, 2025 | 126.42 Mn |
| Mar 31, 2025 | 107.61 Mn |
| Dec 31, 2024 | 113.80 Mn |
| Sep 30, 2024 | 119.99 Mn |
| Jun 30, 2024 | 113.54 Mn |
| Mar 31, 2024 | 117.84 Mn |
| Dec 31, 2023 | 123.55 Mn |
| Sep 30, 2023 | 129.25 Mn |
| Jun 30, 2023 | 134.95 Mn |
| Mar 31, 2023 | 140.66 Mn |
| Dec 31, 2022 | 129.22 Mn |
| Sep 30, 2022 | 134.60 Mn |
| Jun 30, 2022 | 139.99 Mn |
| Mar 31, 2022 | 145.37 Mn |
| Dec 31, 2021 | 150.76 Mn |
| Sep 30, 2021 | 156.14 Mn |